Treatment Plan for Viral Infection
For most viral infections, treatment is supportive only, but specific antiviral therapy is indicated for influenza, COVID-19, and RSV in high-risk populations.
Influenza Treatment
Non-Severe Influenza
For patients at high risk of progression to severe disease, start baloxavir marboxil within 48 hours of symptom onset 1, 2, 3. High-risk factors include:
- Immunocompromised states (hematological malignancies, transplant recipients)
- Chronic cardiopulmonary disease
- Pregnancy
- Age >65 years
- Morbid obesity
Dosing:
- Baloxavir: weight-based dosing (single dose)
- Alternative: Oseltamivir 75 mg twice daily for 5-10 days 4
For patients without high-risk factors, antivirals are not recommended for non-severe influenza 1, 2.
Severe Influenza (Hospitalized Patients)
Oseltamivir 75 mg twice daily is the first-line treatment, started immediately regardless of symptom duration 4, 5.
For severely immunocompromised patients with severe disease, some experts use oseltamivir 150 mg twice daily 4.
If no clinical improvement after 5 days:
- Repeat respiratory testing to assess ongoing viral replication
- Consider extending treatment to at least 10 days
- Consider combining neuraminidase inhibitors with baloxavir 4
For patients with impaired GI absorption, use IV zanamivir or peramivir if available 4.
What NOT to Use for Influenza
Strong recommendation against:
- Antibiotics (unless bacterial co-infection documented) 1, 2
- Corticosteroids 1, 2, 5
- Macrolides (without co-infection) 2, 3
- NSAIDs 2, 3
COVID-19 Treatment
Mild to Moderate COVID-19
For high-risk patients, nirmatrelvir/ritonavir is first-line therapy within 5 days of symptom onset 6, 7.
Dosing (adjusted for renal function):
- eGFR >60: 300 mg nirmatrelvir/100 mg ritonavir every 12 hours for 5 days
- eGFR 30-60: 150 mg nirmatrelvir/100 mg ritonavir every 12 hours for 5 days
- eGFR <30: 300 mg nirmatrelvir/100 mg ritonavir once on day 1, then 150 mg/100 mg once daily days 2-5 6
Critical caveat: Screen for drug-drug interactions before prescribing nirmatrelvir/ritonavir—this is extensive and includes many common medications 6, 7.
Alternative: IV remdesivir for 3 days if nirmatrelvir/ritonavir contraindicated 6.
Second alternative: Molnupiravir when both above options unsuitable 7.
For patients without risk factors, antivirals are not routinely recommended 6.
What NOT to Use for COVID-19
RSV Treatment
Pediatric Patients (<2 years)
Passive immunization with nirsevimab (long-acting) or palivizumab (short-acting) is recommended for prevention during RSV season 4.
Adult Patients
No specific antiviral therapy currently recommended. Treatment is supportive 4.
Diagnostic Testing Strategy
For suspected severe influenza: Use nucleic acid amplification test (NAAT) or PCR—these have the highest sensitivity and specificity 1, 2, 3.
For suspected non-severe influenza in high-risk patients: Use digital immunoassay (DIA) or NAAT for rapid results to guide antiviral initiation 1, 2.
Critical point: Rapid antigen tests have lower sensitivity and should not be used to rule out influenza in hospitalized patients. If negative, confirm with molecular testing 5.
For critically ill patients with lower respiratory tract disease, test endotracheal aspirate or BAL fluid (not just upper respiratory specimens) as viral shedding may persist longer in lower airways 5.
General Principles
Timing is critical: Antiviral benefit is greatest when started within 24 hours of symptom onset for influenza 8 and within 5 days for COVID-19 6, 7.
Do not wait for test results in high-risk patients with compatible symptoms during peak season—start empiric treatment immediately 4.
Vaccination remains the most effective intervention for preventing severe disease from both influenza and COVID-19 5, 7.